We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

REVVITY

Featured Products: More products

Download Mobile App




Simple Colorimetric Assay Determines Human Mercaptalbumin Concentration

By LabMedica International staff writers
Posted on 30 Jun 2022

Human serum albumin (HAS) can take on two forms, mercaptalbumin (HMA) or non-mercaptalbumin (HNA), depending on the redox status of its Cys34. More...

The ratio of HMA and HNA is considered to be a novel biomarker of oxidative stress.

The majority of studies on the redox state of HSA utilize high performance liquid chromatography (HPLC). Several recent studies have also employed mass spectrometry, which yields a higher resolution, thus allowing for finer distinctions between molecular structures. A handful of studies have explored alternative approaches using simple dye-based assays.

Clinical Laboratorians at The University of Tokyo Hospital (Tokyo, Japan) collaborated with colleagues at Nitto Boseki Co. Ltd., (Kawasaki, Japan) measured the concentrations of HMA in serum samples from 36 healthy subjects based on absorption changes of Michler's Hydrol. Michler's Hydrol (4,4′-Bis(dimethylamino)benzhydrol) is a blue dye with a maximum absorption at 612 nm, and its absorption decreases when it reacts with a thiol group.

After processing the samples, the solution was incubated further at room temperature for 20 minutes and absorbance at 612 nm (A612) was measured by a 96-well plate Nivo 3F microplate reader (PerkinElmer, Waltham, MA, USA). To evaluate the performance of the assays, the correlation was determined by a linear regression between the HMA concentrations obtained by Michler's Hydrol assay and corresponding reference concentrations obtained by HPLC and Bromocresol purple (BCP) assays.

The scientists reported that HMA concentrations obtained by Michler's Hydrol assay were highly correlated (r2 = 0.97) with reference values obtained by HPLC (HMA %) and BCP assay (total albumin). The HNA% obtained by Michler's Hydrol and BCP assays combined also gave a good correlation (r2 = 0.96) and a small deviation (average 2.4%) with respect to HPLC as a reference method. The use of the HMA/HNA ratio, which is a function of oxidation of Cys34, is considered a potential biomarker to assess the severity of chronic diseases for which oxidative stress is a significant etiological manifestation.

The authors concluded that the concentrations of HMA in human serum can be measured by Michler's Hydrol assay, which is based on an approximation of HMA concentrations with Michler's Hydrol's colorimetric changes mainly due to thiols. The assay accuracy was significantly improved by pre-incubation of a subset of the samples with an alkylating agent (iodoacetamide) and subtracting their absorption from the absorption of corresponding samples without alkylation. Proportions of HMA and HNA were also obtained by combining Michler's Hydrol assay and the BCP assay (for total albumin concentration). The results correlated well with HPLC, which has been established as a standard method for HMA/HNA measurement. The study was published on June 8, 2022 in the journal Practical Laboratory Medicine.

Related Links:
The University of Tokyo Hospital
Nitto Boseki Co. Ltd
PerkinElmer

 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
New
Gold Member
Platelet Function Analyzer
PL-12
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.